Background. The pathophysiological mechanisms of secondary neurological injury after traumatic brain injury are complex. Posttraumatic biochemical reactions include parenchymal inflammation, free radical production, increased intracellular calcium and lipid peroxidation and nitric oxide production. The relative importance of each mechanism is unknown in brain contusions. This study was undertaken to investigate protection by the neuroprotective and= or anti-inflammatory drugs that have different putative mechanisms of action: colchicine, dexamethasone, tirilazad mesylate and nimodipine.
Introduction
The clinical course of brain trauma is variable and there are still no successful neuroprotective treatment strategies as the pathology of traumatic brain injury (TBI) is complex. Experimental findings have helped to elucidate pathophysiological mechanisms related to post-traumatic cell death and associated neurological impairment. Necrosis, apoptosis, mitochondrial dysfunction, inflammatory and excitotoxic cellular damage can been seen after TBI [3, 28, 32, [54] [55] [56] . Each of these mechanisms of cellular damage initiated can be caused by the trauma but also cause further cascades of events mediated by endogenous signals that can lead to further secondary neurological injury [39] . Additionally, delayed biochemical reactions such as parenchymal inflammation, intracellular production of free radicals, increased intracellular calcium levels and lipid membrane peroxidation contribute to tissue damage following neuronal trauma [39] . This knowledge has led to the development of targeted neuroprotective strategies to limit posttraumatic secondary cell death and improve neurological recovery [12] . Post-traumatic treatment with dexamethasone has in some studies indicated a neuroprotective potential but phase III clinical studies have failed to confirm this effect [52] . Colchicine has some anti-inflammatory properties [40, 50] also in the context of experimental brain injury [30] . Tirilazad mesylate and nimodipine are neuroprotective but their effects on clinical TBI are not clear [52] . Therefore, there is a need of further preclinical studies to define their effectiveness and pharmacology, before their clinical potential can be assessed. Nitric oxide is a universal mediator of biological effects in the brain, which has been implicated in the pathophysiological processes of traumatic brain injury [7, 47, 63] . Experimental studies and a recent study on human brain tissue from patients operated on for brain contusion have indicated a posttraumatic up-regulation of inducible nitric oxide synthase (iNOS) following brain trauma [8, 15, 16, 53, 62] . iNOS is a possible actor in inflammatory reactions and may catalyse synthesis of harmful NO in the injured brain [35, 48] . We presumed that the relative importance of different pathogenetic mechanisms such as Ca-overload, free radical damage, inflammation and ischemia may differ in different traumatic injuries and wanted to analyse their relative contributions. This experimental study was undertaken to increase the knowledge of neuronal protective properties of the potentially neuroprotective and=or anti-inflammatory drugs colchicine, dexamethasone, tirilazad mesylate and nimo-dipine by assessing their effects in experimental contusions. All drugs have different putative mechanisms of action and we hypothesized that the relevant pathogenic mechanisms could be further elucidated from a possible differential influence on neuronal degradation. Their protective capacity was analysed by estimation of their effect on neuronal degeneration and survival. Finally, their potential to affect one important mediator of intracerebral inflammation, iNOS, was assessed; all of these substances may theoretically affect iNOS synthesis.
Materials and methods

Tissue preparation
85 male Sprague-Dawley rats weighing 310-360 grams were anaesthetized by injecting 0.2 ml of Hypnorm (fentanyl citrate, 0.315 mg=ml and fluanisone, 10 mg=ml, Janssen, Belgium) intramuscularly. 0.3 ml of Xylocain-Adrenalin, 5 mg=ml of lidocain hydrochloride, and 5 mg=ml of adrenaline (Astra, Sweden) were injected subcutaneously, along the sagittal midline of the skull, at the site of skin incision. The brain contusion was mimicked experimentally using a modification [31] of the weight-drop model described by Feeney et al. [14] . The animals were put into a stereotactic frame, and after skin incision, a hole in the skull (2 mm in diameter) was drilled at a point 2 mm posterior and 2 mm lateral to the bregma. A standardized small parietal contusion was produced by dropping a weight (24 grams) on a piston from a height of 6.5 cm. The maximal compression of the dura was set at 3 mm (day 0). A schematic drawing showing the lesion in a coronal section is illustrated in Fig. 1A . The skin was sutured and allowed to recover. They showed normal grooming and feeding behaviour within 12 hours after surgery. The animals were divided into 5 experimental groups. In 2 animals, postoperative wound infection was detected. The inflammatory response caused by infection could interfere with the posttraumatic cellular response and these animals were therefore excluded from the study. The animals received first bolus with drug or control treatment at four hours after trauma, intraperitoneally. One group (n ¼ 15), serving as control group, received isotonic NaCl 9 mg=ml (Kabi Pharmacia, Sweden), 1.5 ml once a day. The animals in the 4 different treatment groups received one of the following drugs; Colchicine (Apoteksbolaget AB, Sweden) (n ¼ 15) 0.2-mg=kg once daily, a dose optimised to reduce inflammation in experimental brain contusion [30] , Dexamethasone (Apoteksbolaget AB, Sweden) (n ¼ 14) 1 mg=kg once daily, which was previously found to be beneficial in experimental brain contusion [30] , Tirilazad mesylate (n ¼ 14) 10 mg=kg (Upjohn Laboratories, Kalamazoo, Michigan, USA) once a day, an optimal neuroprotective dose in several experimental focal cortical injuries [44, 58] . Nimodipine (n ¼ 15) 360 mg=kg (Bayer AB, Leverkusen, Germany) twice a day (every 12 hours) in order to mimic the daily dose used for intravenous infusion in the treatment of subarachnoid haemorrhage patients in Sweden. All drugs were dissolved in NaCl 9 mg=ml except for Nimodipine, since it already was in fluid. Animals were equally divided into three survival groups and sacrificed by inhalation of carbon dioxide (8 l=min for 2 min) at 24 hours, 5 days or 14 days after the trauma. 10 animals (2 per group) were sham-operated on, (i.e. the animals underwent the same anaesthetic and surgical procedure except for the contusional trauma) and sacrificed at 24 hours after trauma. The brains were removed, snap frozen in 2-methylbutane and stored at À70 C. 14 mm coronal cryosections were cut through the centre of the traumatized area, dried at room temperature for 1-2 hours and stored at À20 C. Prior to immunohistochemical staining, the sections were dried at room temperature for 30 minutes, rehydrated in diluted phosphate buffered saline (PBS) and fixed in 4% buffered proformaldehyde at room temperature for 10 minutes. The local ethics committee approved all experiments.
Immunohistochemistry
The sections were incubated in 0.3% hydrogen peroxide for 30 min to quench endogenous peroxidase. The indirect peroxidase method was performed for iNOS and albumin stainings. iNOS antibody (1:800, Transduction Laboratories, Lexington, KY, USA) and anti-albumin (1:000; Cappel Research Products, NC, USA) were used. Peroxidase conjugated goat anti-rabbit Ig (Jackson ImmunoResearch Lab. Inc., West Grove, PA, USA) dilution 1:250 was used as conjugate. Normal goat serum (NGS) was used to prevent non-specific conjugate binding. All conjugates were absorbed with normal rat serum to minimize cross reactivity with rat Ig. After washing, the bound peroxidase was visualized by incubation for 5 minutes with a diaminobezidine substrate kit (SK-4100, Vector Laboratories Inc., CA, USA). Sections were counterstained with haematoxylin, dehydrated and mounted with DPX (Distrene 80, dibutyl phthalate, xylene, BDH Laboratory Supplies Poole, UK). For NeuN stainings, a Vectastain Elite avidin-biotinylated enzyme complex (ABC) peroxidase kit (Vector Laboratories) was used. In brief, before the sections were incubated with the NeuN primary antibody (1:500, Chemicon International, Temecula, CA), blocking serum (PBS plus 0.3% Triton plus 1% BSA) was used to prevent non-specific conjugate binding to the primary antibodies.
An avidin-biotin blocking step was then performed with ABC, to prevent non-specific conjugate binding to endogenous biotinylated proteins. The sections were then incubated with the primary antibody NeuN over night at þ4 C. After washing, the indirect peroxidase method was used for detection of the primary antibodies. Biotin-conjugated goat anti-rabbit immunoglobulin (1:200; Jackson ImmunoResearch Laboratories) was used as conjugate. After washing, the sections were incubated with the ABC standard kit for 1 hour at room temperature (RT). Next, the sections were washed with Tris-HCl (IB70162; Eastman Kodak Co., New Haven, CT). After washing, the bound peroxidase was detected via incubation for 3 minutes with a diaminobezidine substrate kit (SK-4100, Vector Laboratories Inc., CA, USA). Finally, sections were dehydrated and mounted with DPX. For double labelling, immunofluorescence technique was performed. NGS was used to prevent non-specific conjugate binding. The sections were incubated over night in a mixture of polyclonal anti-iNOS(1:800, Transduction Lab) with one of the cell marker antibodies (NeuN: 1:500, Chemicon International, Temecula, CA; ED-1: 1:4000, Serotec, Oxford, UK; W3=13: 1:1000 Sera-lab, Sussex, UK; GFAP: 1:500, Dakopatts a=s, Glostrup, Denmark). After washing, a mixture of indocarbocyanine (Cy3) conjugated goat anti-rabbit Fab 2 fragments (Jackson ImmunoResearch Lab) dilution 1:800 and fluorescein isothiocyanate (FITC) conjugated goat anti-mouse Fab 2 fragments (Jackson ImmunoResearch Lab) dilution 1:150 was applied for 1 hour at room temperature. After washing, the slides were mounted with glycerol: PBS, 2:1. All conjugates were diluted in PBS containing 4% bovine serum albumin. The primary antibodies were diluted in PBS containing 1% bovine serum albumin. 
Neuronal degeneration and iNOS expression in experimental brain contusion
Fluoro-Jade staining
Fluoro-Jade is a fluorochrome capable of selectively staining degenerating neurons [59] . The applications for Fluoro-Jade (FJ) are generally similar to those for suppressed silver staining [59] . F-J stains degenerating neurons in their entirety including cell bodies, dendrites, axons and terminals [59] . The exact mechanism by which FJ stains degenerating neurons is not known, but it has been presumed that strongly basic molecules are produced in the neuron during the degenerating process, which causes a high affinity for the strong acidic FJ [59] . Moreover, FJ stains injured neurons regardless of the nature of the insult, which include both apoptotic and necrotic cell death [59] . Stainings for Fluoro-Jade were performed to detect neuronal degeneration in the experimental groups after trauma. Prior to staining, the sections were dried at RT for 1 hour, fixed in 4% buffered proformaldehyde for 10 minutes. After washing in PBS, the sections were rinsed in distilled water and incubated with 0.00002% Fluoro-Jade in 0.1% acetic acid for 30 minutes in RT in coplin jar on shaker. After washing in distilled water, sections were dries on a hot plate (approximately 50 C) and mounted with DPX.
TUNEL staining
The sections were prepared the same way as described for immunohistochemistry except that they were post-fixed in ethanol:acetic acid 2:1 for 5 minutes at À20 C prior to the staining procedure. The TUNEL reaction was carried out with the ''In situ cell death detection kit, fluorescein'' (Boehringer Mannheim, Bromma, Sweden) at 37 C for 30 minutes. The slides were washed in PBS and mounted with Glycerol:PBS (2:1) and stored at 4 C. Fluorescence double labelling for TUNEL and cellular markers (ED-1, W3=13, NeuN, GFAP) was performed. The same TUNEL procedure was followed but before mounting, the sections were incubated with NGS for 30 minutes at RT and the primary antibody for NeuN was applied and incubated over night at 4 C. After washing, an indocarbocyanine(Cy3)-conjugated goat anti-rabbit Fab 2 fragments (Jackson ImmunoResearch Lab) dilution 1:800 was applied for 60 minutes at RT. The section were thereafter washed and mounted with Glycerol:PBS.
Controls
Normal brain sections were used as positive control for NeuN-, GFAP-and albumin-stainings. Normal spleen sections were used as positive control for iNOS-, ED-1-and W3=13-stainings and as negative controls for NeuN and GFAP. Reactive lymph nodes were used as positive control for TUNEL-staining. Brain sections from sham operated rats and sections of the contra lateral hemisphere of the contused rats were used as negative controls for iNOS-, ED-1-, W3=13-, TUNEL-and Fluoro-Jade-stainings. 1% BSA instead of primary antibodies was used to rule out the possibility of non-specific conjugate binding. Fig. 1A . Two consecutive sections from each animal stained for iNOS, FJ and TUNEL were analysed and averaged to constitute one observation. Similar to earlier observations following experimental TBI [9, 55] , TUNEL-positive cells exhibited both apoptotic and non-apoptotic morphologies. Cells were differentiated as being apoptotic and non-apoptotic based on TUNELpositive staining and morphological hallmarks of apoptosis, including membrane blebbing, chromatin condensation, nuclear shrinkage and cytoplasm condensation and disintegration. Subsequently, apoptotic cells exhibit intense nuclear staining and breakdown of the cell surface into spherical apoptotic bodies. Swollen, diffusely TUNEL-stained cells not exhibiting apoptotic morphology were considered to be non-apoptotic. Only TUNEL-positive cells with apoptotic morphology were counted. The relative percentage of TUNEL-positive neurons of all TUNEL-positive cells (with apoptotic morphology) was estimated, under high power (400Â), by counting the number of TUNEL-positive that co-expressed the neuronal cell marker NeuN of 100 TUNEL-positive cells counted in a randomly chosen area with TUNEL-positive cells with apoptotic morphology. Evaluation of double labelling was performed using a Leica DMRB TM fluorescence microscope with Leica filter cube L4 (excitation filter: 450-490 nm, suppression filter: 515-560 nm) for FITC labelling and with Leica filter cube N2.1 (excitation filter: 515-560 nm, suppression filter edge wavelength: 590 nm) for Cy3 labelling. Photomicrographs for double labelling illustrations were obtained by changing the filter cube without altering section position or focus.
Evaluation of iNOS, Fluoro-Jade and TUNEL-stainings
Evaluation of NeuN-staining
Residual neurons that expressed NeuN were calculated at the final end-point 14 days after trauma. Evaluation of NeuN-positive cells was performed using a Leica DM4000B TM light microscopy and KODAK 1D Image Analysis Software (Eastman Kodak Company, Scientific Imaging Systems Rochester, NY 14650). Photomicrographs of an area of 0.49 Â 0.49 mm were taken under low power (50Â) of the medial perilesional cortex (including the penumbral zone) using a Leica DFC 320 camera and software program Adobe Photoshop 7.0. Photomicrographs (0.49 Â 0.49 mm) were also taken in the contra lateral hemisphere to detect possible differences of NeuN-expression between the treatment groups in uninjured tissue. Image analysis of NeuN-positive cells was performed in KODAK 1D Image Analysis Software by Regions of Interest (ROI). Three consecutive sections with an interval of approximate 40 mm from each animal in the same localization in the contusions were analysed and averaged to constitute one observation.
Evaluation of albumin-staining
For evaluation of albumin staining, the staining pattern for albumin immunoreactivity was scored: 0 ¼ distinct intraluminal albumin immunoreactivity, 1 ¼ intraluminally stained vessels with a surrounding 
Statistical analysis
Data are presented as means þ standard deviation. One-way analysis of variance (ANOVA) and Dunnetts test were used for evaluation of cell numbers in Fluoro-Jade, NeuN, TUNEL and iNOS stainings. P < 0.05 was considered significant. No statistical analysis was performed for albumin staining or the relative percentage of cellular sources of TUNEL-positive cells.
Results
We analysed the expression of iNOS, neuronal survival, neuronal degeneration, cellular DNA fragmentation and post-traumatic oedema after an experimental brain contusion in rats treated with colchicine, dexamethasone, tirilazad mesylate and nimodipine. The expression of iNOS was analysed with immunoperoxidase staining. Extracellular oedema was estimated by albumin staining. Cellular DNA-fragmentation with apoptotic morphology was analysed with TUNEL staining. Neuronal survival and degeneration was analysed with NeuN-and Fluoro-Jade staining, respectively. Identification of cells expressing iNOS and TUNEL was done with immunofluorescence double labelling.
Neuronal degeneration (Fluoro-Jade) and neuronal survival (NeuN) At 24 hours after trauma, the number of cells positive for Fluoro-Jade staining was significantly higher in the control group than in the treatment groups (colchicine and tirilazad mesylate; p < 0.05, dexamethasone and nimodipine; p < 0.01) (Fig. 2) . The number of FluoroJade-positive cells decreased in all groups at later timepoints after trauma. At 5 and 14 days after trauma, the number of Fluoro-Jade-positive cells was significantly higher in dexamethasone (p < 0.05 and p < 0.01) treated animals than in controls. In the other treatment groups (colchicine, tirilazad mesylate, nimodipine), the expression of Fluoro-Jade was less than in controls at 5 and 14 days after trauma, but not significantly so (Fig. 2) . All Fluoro-Jade positive cells showed neuronal morphology. Examples of Fluoro-Jade-positive cells are shown in Fig. 1E . The number of NeuN-positive cells in the penum- bral zone at 14 days after trauma was significantly higher (p < 0.01) in animals treated with colchicine or tirilazad mesylate compared with controls (Fig. 5) . The number of NeuN-positive cells was also higher in animals treated with dexamethasone or nimodipine but not statistically significant. No significant differences of number of NeuN-positive cells were detected in the contra lateral hemisphere between the treatment groups or controls (data not shown). No Fluoro-Jade positive neuronal cells were detected in sham-operated animals (data not shown).
Cellular apoptosis (TUNEL)
At 24 hours after trauma, the number of cells positive in TUNEL staining with apoptotic morphology was high in all groups. No significant differences were detected between the treatment groups and the controls (Fig. 3) . At 5 days after trauma, the number of TUNEL-positive cells was significantly higher in tirilazad mesylate (p < 0.01) treated animals compared with the controls whereas no significant differences were detected in the other treatment groups. Between 5 and 14 days after trauma, the number of TUNEL-positive cells did not change significantly. The cells positive for TUNEL showed morphologies of granulocytes, macrophages and neurons and co-expression of W3=13, ED-1 or NeuN (Fig. 6B, D, F) was detected. At 24 hours, the relative proportion of TUNEL-positive cells that coexpressed NeuN was higher in controls (53.2%) compared with treatment groups (Colchicine; 31.2%, Dexamethasone; 26.6%, Tirilazad Mesylate 28.4% and Nimodipine; 35.4%). At 5 and 14 days, the majority (71.6-86.4%) of TUNEL-positive cells co-expressed non-neuronal cell markers in all groups with no significant differences between controls or treatment groups (data not shown). No TUNEL-positive cells were detected in sham-operated animals (data not shown).
iNOS expression
At 24 hours after trauma, the number of iNOS-positive cells was lower in all treatment groups compared Neuronal degeneration and iNOS expression in experimental brain contusion with the controls. The difference was particularly significant (p < 0.01) in colchicine, tirilazad mesylate and nimodipine treated animals. At 5 and 14 days after trauma, no significant differences between controls and treatment groups were detected (Fig. 4) . Positive cells showed morphologies of granulocytes and mononuclear phagocytes and neurons (Fig. 4) . Double labelling assays for iNOS plus ED-1 (mononuclear phagocytes), W3=13 (PMN's or lymphocytes), NeuN (neurons) or GFAP (astrocytes) were performed. iNOS-positive cells predominantly co-expressed W3=13 or ED-1 (Fig. 6A, C) . At 24 hours after trauma, a few iNOS-positive cells 
Analysis of vasogenic oedema
To study the development of vasogenic oedema in this model, coronal sections through the contusion were stained for albumin. This method is only semi-quantitative for oedema but is useful for determining whether a vasogenic component is present. In sham-operated animals, distinct intraluminal albumin immunoreactivity was seen in both hemispheres (Fig. 1F) . At 24 hours after trauma, an intense, diffuse parenchymal albumin staining with non-discernible intraluminal staining was seen in a large area around the contusion (data not shown). In an intermediary zone between diffusely and normally stained tissues, intraluminally stained vessels with a surrounding diffuse halo was seen, indicative of less severe blood-brain barrier (BBB) dysfunction. The contra lateral hemisphere was never affected (data not shown). No difference was detected between the experimental groups at 24 hours after trauma. At 5 days after trauma, a slightly less intense parenchymal staining was seen in rats treated with dexamethasone compared with controls ( Fig. 1D and B) . In the other treatment groups, no difference was detected compared with controls at 5 days after trauma (data not shown). At 14 days, the parenchymal albumin immunoreactivity was decreased but still present; no differences were detected between the treatment groups and the controls (data not shown). Taken together, trauma caused a similar vasogenic oedema in all groups, which was, however, less pronounced at 5 days after trauma in animals treated with dexamethasone.
Discussion
We demonstrated an attenuated early neurodegeneration by a decreased number of Fluoro-Jade (FJ)-positive cells at 24 hours in all treatment groups. The effect appeared to be specific for neurons, since the total number of TUNEL-positive cells did not differ between the groups. FJ is a well-established marker for degenerating neurons [59] , whereas TUNEL recognizes DNA-fragmentation in all cells [18] . At 5 and 14 days, however, an increase of neuronal degeneration and cellular apoptosis was seen with dexamethasone and tirilazad mesylate, indicating drug-related changes of the dynamics of neuronal degeneration and apoptosis. After 14 days, the number of surviving NeuN-positive neurons was significantly higher in the colchicine and tirilazad mesylate groups. The data underscore the necessity not to evaluate neuroprotection only at early time-points. The lack of a statistically significant protection at 14 days in the dexamethasone and nimodipine groups may reveal a type-2 error, but is also compatible with clinical findings.
Colchicine
Colchicine is anti-inflammatory and modulates chemokine and prostanoid production, inhibits neutrophils, macrophages and endothelial cell adhesion molecules and thereby interferes with the inflammatory reaction [30, 50] . We detected a significant decrease of degenerating neurons in colchicine-treated animals at 24 hours after trauma. Neuronal survival was significantly increased in the penumbral zone at 14 days. Colchicine has shown beneficial effects in ischemic lesions [19, 20] and following experimental brain contusion [30] but the finding of decreased neuronal degeneration in experimental contusion was new. The findings suggest that anti-inflammatory therapies targeted on macrophages= microglial activation may be beneficial for contusional injuries with a moderate energy transfer. The protective effect was specific for neurons since TUNEL-staining of inflammatory cells and glia was unaffected.
Colchicine destabilises microtubule and interferes with inflammation in several steps. Neuroprotective mechanisms are probably related to the anti-inflammatory properties. Colchicine inhibits the synthesis of TNF-, a cytokine known to be involved in the inflammatory response following TBI [3, 32] . Furthermore, Colchicine-induced inhibition of endothelial cell adhesion molecules and destabilisation of the microtubules in leucocytes might have impaired the posttraumatic migration and invasion of inflammatory cells from the blood stream into the brain parenchyma, which occurs following TBI [32] . Its anti-gout effect appears to be mediated through its early interference with polymorphonuclear cells (PMN's) [3, 32] . PMN's are also relevant in early CNS posttraumatic inflammation [3] .
Dexamethasone
Corticosteroids have anti-inflammatory effects and act on intracellular receptors to inhibit virtually all functions of cellular and humeral inflammatory responses. They also have an antioxidant potential through inhibition of lipid peroxidation in CNS injury [2] . Dexamethasone was the only drug that indicated an effect on BBB function in this study; a morphological attenuation of albumin extravasation was seen at day 5. Damage to the blood vessels in the brain parenchyma is produced by the trauma itself and a possible early drug-induced effect on membrane stability may therefore be obscured. Dexamethasone appeared to reduce post-traumatic vasogenic brain oedema, which is in agreement with other studies [30, 33] . The effect on albumin extravasation could be a directly membrane stabilizing effect or mediated by its anti-inflammatory properties.
At 24 hours, the number of FJ-positive cells was reduced by dexamethasone. The total number of TUNEL-positive cells was unchanged but the relative percentage of TUNEL-positive cells that co-expressed NeuN was lower than in controls at 24 hours. These findings indicated that dexamethasone had an early neuroprotective effect without affecting other cell-populations. However, later the number of FJ-positive cells became higher than in controls and the total number of residual neurons in the penumbral zone at 14 days after trauma was not significantly different from controls. Two explanations are possible: Dexamethasone treatment may have delayed the post-traumatic inflammatory reaction and retarded neuronal degeneration. Different mechanisms of neuronal degeneration appear to be relevant at different times after trauma for this model of brain contusion [64] . Another possibility is that prolonged dexamethasone treatment had direct neurodegenerative effects. Corticosteroids in high doses are known to be able to induce neuronal apoptosis in the CNS [29, 49] . The potential neuroprotective properties of dexamethasone are thus contradictory. Experimental studies have shown that corticosteroids are protective following subarachnoid haemorrhage and brain trauma [24, 26] , while clinical studies have failed to detect a general neuroprotective effect [1, 52] . The present study is to our knowledge the first experimental analysis of dexamethasone treatment and neuronal cell death in a rodent model of brain contusion. An early effect on neurodegeneration seemed clear. This model mimics brain contusion [14] . Interestingly, a multicenter study [21] showed a protective effect of corticosteroids on patients with brain contusions. Additional experimental data are needed to define patient categories and drug regimen for corticosteroid treatment in head injury. It is possible that corticosteroids in the future may prove clinically useful for certain subgroups of TBI patients.
Tirilazad mesylate
Trauma to the CNS leads to mitochondrial dysfunction and production of reactive oxygen species (ROS) that cause lipid peroxidation of cell membranes, resulting in membrane disintegration and increased micro vascular permeability [36] . ROS are also activators for neutrophils in damaged tissues, which contribute to the inflammatory reaction [36] . Lazaroids inhibit lipid membrane peroxidation acting through free radical scavenging and membrane stabilization and thereby function as neuroprotective antioxidants after CNS injury [36] , but may thus also act anti-inflammatorily. Tirilazad mesylate was beneficial in experimental diffuse and focal injuries [10, 25, 44] , but phase III clinical trials have failed [42, 43, 52] . In our contusion model, the significantly decreased number of degenerated neurons and the reduced relative percentage of NeuN=TUNEL-positive cells at 24 hours, and increased neuronal survival at 14 days indicated a neuroprotective effect in this kind of contusional injuries. These findings are, to our knowledge, novel. Surprisingly, the total number of TUNELpositive cells was increased at 5 days after trauma. Tirilazad mesylate thus spared neurons but increased cellular death in the pool of cells encompassing leucocytes and macrophages. An antioxidant effect of tirilazad mesylate, resulting in lower amounts of free radicals causing DNA damage and neurotoxicity was possible and the latter finding indicated an overall anti-inflammatory effect.
Nimodipine
The calcium-channel blocker nimodipine is standard treatment for patients with nontraumatic subarachnoid haemorrhage. In clinical traumatic brain injury, nimodipine was beneficial in younger patients and in patients with posttraumatic subarachnoid haemorrhage [27, 37] , although this conclusion is debated since several trials of nimodipine treatment in human head injury were negative regarding their primary endpoints [51, 52, 60] . Interestingly, subgroup analysis of clinical trials suggested a better outcome with nimodipine treatment in the patients with intra-axial contusions without extra cerebral haematomas [45] . The effect of nimodipine treatment in experimental head injury has been investigated to a limited extent and shown contradictory results [11, 61] . Our results demonstrated a significant early decrease of degenerated neurons, both Flouro-Jade positive cells and NeuN-positive=TUNEL-positive cells, which supported a possible neuroprotective posttraumatic effect. A statistically significant difference did not remain at day 14. Overall anti-apoptotic effects were not seen in other cell-populations. Although the findings may reflect insufficiently powered analyses, an L-channel specific Ca-antagonist was not the best choice for neuroprotection following contusion.
iNOS expression
All test drugs may theoretically affect iNOS synthesis and iNOS has been implicated as a possible mediator of inflammation associated brain damage [15, 16] . Nitric oxide (NO) is produced in the brain by three different izo-enzymes; the endothelial form (eNOS) [5] , the neuronal form (nNOS) [46] and the inducible form (iNOS) [65] . eNOS and nNOS constitutively produce NO in a calcium=calmodulin-dependent manner, while iNOS produces NO independently of calcium and only under certain pathological conditions [35] . Peroxynitrite (ONOO À ) is synthesized from NO and super oxide anion (O 2 ÁÀ ) radicals and is a powerful oxidant that is neurotoxic and may lead to neuronal necrosis and apoptosis [38] . iNOS derived NO-production is implicated in the pathophysiological mechanisms of secondary brain injury after trauma via peroxynitrite-related effects [22] . It is known that TBI causes release of the pro-inflammatory cytokines tumour necrosis factor-(TNF-), interleukin (IL)-1 and increased levels of IL-6 [3] , also for this model of brain contusion [32] . TNF-and IL-1 are two major inducers of iNOS mRNA transcription and act through activation of NFB pathway [17] . IL-6 has also been implicated as an additional factor for induction of iNOS mRNA, acting through other signalling pathways [17] . TBI also causes cellular depolarisation, increased extracellular glutamate levels, NMDA receptor activation and cellular calcium influx [13, 34, 56] . These various biochemical effects make several different targets for pharmacological intervention possible. In the present study, post-traumatic administration of dexamethasone, colchicine, tirilazad mesylate or nimodipine reduced the expression of iNOS. We demonstrated a significant decrease of iNOS positive cells in animals treated with colchicine, tirilazad mesylate and nimodipine at 24 hours after trauma. Although dexamethasone appeared to reduce iNOS expression early after trauma, the reduction was not significant compared to the control group. Under the circumstances, assuming no effect at all would seem to risk a B-type error. The effect on iNOS expression was similar in colchicine, tirilazad mesylate and nimodipine groups, although they have different mechanisms of action and despite the fact that their neuroprotective properties are presumably linked to mechanisms other than iNOS expression. The early decrease in iNOS expression that was detected in all groups is compatible with a drug effect on the iNOSmRNA expression. All drugs have potential effects on iNOS synthesis; dexamethasone and colchicine decrease iNOS mRNA=protein expression by inhibition of NFkB and depolymerization of microtubules respectively [17, 41] . Additionally, tirilazad mesylate like other antioxidants may reduce iNOS transcription [57] . The calcium channel-blocker nimodipine also reduced iNOS expression in the present study, which to our knowledge has not been demonstrated before in experimental brain trauma, but supports findings in focal ischemia [66] . Furthermore, Cattaruzza et al. 2000 suggested that the effect on iNOS was exerted on the transcriptional level [6] . Another possibility would be that the different drugs limited secondary neurodegeneration via their intended mechanisms, and that decreased cellular injury limited secondary iNOS synthesis. The nonsignificant differences of iNOS expression seen between treatment groups and controls at later time-points (5 and 14 days) indicates that the drugs had the most potent effect on iNOS induction early after injury. The data are compatible with a hypothesis that iNOS may be a common pathway for early neuronal injury in this model. The timing of iNOS decrease and FJ decrease, and regardless of the intended mechanism of action, the effect on FJ-positive cells and iNOS expression was similar in all treatment groups. This hypothesis will be further tested in experiments with specific inhibitors and enhancers of iNOS and with iNOS knockout animals. It is possible that careful dose-response studies with single or combined drugs will give further understanding on importance of iNOS attenuation and the interplay of protective strategies in head trauma. The determination of possible common pathways is of great clinical importance.
In conclusion, we demonstrated that posttraumatic treatment with dexamethasone, colchicine, tirilazad mesylate and nimodipine reduced early neuronal degeneration in this trauma model for focal brain contusion while other effects may be detectable in traumatic haematomas or diffuse injuries. The findings were based on adequate drug doses, but additional titration of dosage, although laborious, may refine data such as these. In this setting, all drugs had some neuroprotective properties and all attenuated early iNOS-synthesis, but only colchicine and tirilazad mesylate enhanced final neuronal survival at 14 days. These data underscore the need to follow dynamics early as these effects may disappear in the long run. Prior to clinical trials functional assessments are necessary in preclinical models of TBI to further evaluate drug-related neuroprotection. In the present context, however, functional assessments would not be practical and we considered crude neuronal survival to be a relevant surrogate endpoint that allows quantitative data in small treatment groups; the ethical aspects have to be carefully considered in these experiments. The present findings would support that neurotoxicity after moderate energy contusion involves parenchymal inflammation, increased levels of free radicals and intracellular Ca 2þ and that NO derivable from iNOS was a possible common pathway. Finally, the pathogenic mechanisms of brain contusion with moderate energy transfer were best attenuated by the free radical scavenger tirilazad mesylate and the anti-inflammatory agent colchicine.
